Tech Company Financing Transactions
Precede Biosciences Funding Round
Precede Biosciences, based in Boston, scored $57 million in funding from 5AM Ventures, Binney Street Capital and Bristol Myers Squibb.
Transaction Overview
Company Name
Announced On
10/10/2023
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Design Center Place 19-500
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Overview
We've experienced significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a platform that uncovers actionable disease-defining transcriptional biology using a simple blood test. Our mission is to partner with developers of new medicines and to advance our own diagnostic tests, working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that's precise to the biology of their disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rehan Verjee
Browse more venture capital transactions:
Prev: 10/10/2023: Propify venture capital transaction
Next: 10/10/2023: Tidalflow venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs